Public Health Emergency - Leading a Nation Prepared
Containing a pandemic will require layered end-to-end solutions: better diagnostics, improved therapeutics, and vaccines produced in the U.S. using cutting-edge technologies. Dr. Kadlec explains how ASPR is taking action to prepare for the next pandemic.
To prepare for the next influenza pandemic, BARDA is investing $226 million to increase U.S. manufacturing capacity of Sanofi Pasteur’s recombinant influenza vaccine, which is faster and more flexible than traditional egg-based technology.
BARDA will support the advanced development of the new testing technology, known as host-response testing, under a 14-month contract with Inflammatrix Inc. The three diagnostic tests in development are for use on a point-of-care test system with results expected within 20-30 minutes.
Sepsis is a serious public health threat, killing approximately 270,000 Americans each year. BARDA is partnering with Cytovale to advance the development of a diagnostic that uses microfluidics, high-speed imaging, and machine learning to identify sepsis in less than 10 minutes! Rapid diagnosis can save lives and enhance health security in the U.S.
BARDA DRIVe is joining forces with Beckman Coulter Diagnostics to develop a digital diagnostic based on a machine-learning algorithm that may detect sepsis earlier. It will combine clinical data from lab tests and patient data from electronic health records in a predictive algorithm. Early detection of sepsis is essential to saving lives in emergency departments and other hospital settings.
